. 2012 Jun 12;9(6):e1001237. doi: 10.1371/journal.pmed.1001237

Table 2. Coronary heart disease deaths prevented or postponed due to changes in treatment uptake between 2000 and 2007 in England and stratified by deprivation quintiles.

Treatment by Patient Groups	England: DPP				By IMD: DPP
	n	Percent	Percent Lower limit^a	Percent Upper limit^a	n Most Affluent	n IMDQ2	n IMDQ3	n IMDQ4	n Most Deprived
STEMI ^b	−130	−0.3	*−0.8*	*0.5*	−6	−27	−28	−31	−38
Thrombolysis	−118				−22	−23	−21	−23	−29
Aspirin	24				5	4	5	3	7
B-blocker	4				1	0	1	1	2
ACE inhibitor or ARB	5				0	0	2	1	2
Clopidogrel	65				12	14	14	13	12
Primary PCI	139				30	28	28	27	25
Primary CABG	1				0	0	0	0	0
CPR in hospital^c	−252				−33	−51	−57	−53	−57
NSTEACS ^b	295	0.8	*0.0*	*2.2*	57	59	62	53	65
Aspirin and heparin	341				54	68	68	63	88
Aspirin alone	−114				−15	−24	−21	−21	−31
PG IIB/IIIA inhibitors	−1				−2	−1	0	0	2
ACE inhibitor or ARB	44				6	8	9	10	10
B-blocker	27				5	5	6	5	6
Clopidogrel	203				36	40	46	41	40
CABG surgery	1				2	1	0	0	−1
PCI	54				11	10	12	12	10
CPR in hospital^c	−259				−40	−48	−58	−55	−58
Secondary prevention post MI ^b	3,510	9.2	*7.2*	*11.4*	640	775	746	711	639
Aspirin	351				65	69	76	87	55
B-blocker	862				158	197	194	167	146
ACE inhibitor or ARB	903				166	200	190	175	172
Statin	1,303				241	280	269	268	245
Warfarin	92				8	30	17	15	21
Rehabilitation^d	0				0	0	0	0	0
Secondary prevention post revascularisation ^b	590	1.5	*1.2*	*1.9*	112	121	128	117	110
Aspirin	45				10	10	11	8	7
B-blocker	154				29	31	34	31	30
ACE inhibitor or ARB	179				35	37	37	34	36
Statin	174				31	36	38	37	32
Warfarin	0				0	0	1	0	−1
Rehabilitation (post CABG)^d	0				0	0	0	0	0
Rehabilitation (post PTCA)	36				7	7	7	7	7
Chronic stable CAD ^b	4,835	12.7	*9.6*	*16.8*	851	1,007	1,015	1,016	955
Aspirin in community	818				139	159	176	179	165
Statin in community	2,488				443	523	526	510	485
ACE inhibitor or ARB	1,292				241	281	268	261	241
CABG surgery	236				27	44	45	57	63
Heart failure - hospital ^b	250	0.7	*0.5*	*0.8*	42	47	53	59	51
ACE inhibitor	49				8	9	10	10	11
B-blocker	39				6	8	8	9	9
Spironolactone	37				6	7	8	8	8
Aspirin	126				21	22	27	32	23
Heart failure - community ^b	3,335	8.8	*7.3*	*10.4*	564	689v	732	711	641
ACE inhibitor or ARB	737				125	158	171	146	137
B-blocker	1,592				284	325	353	338	292
Spironolactone	617				105	134	120	129	129
Aspirin	389				50	72	88	97	83
Hypertension treatment ^b	1,800	4.7	*1.8*	*9.9*	357	411	408	345	277
Hyperlipidemia treatment (statins) ^b	5,300	13.9	*5.0*	*31.8*	1,054	975	1,305	1,194	772
Total treatment contribution ^b	19,780	52.0	*40.2*	*69.7*	3,670	4,055	4,420	4,166	3,471

Subtotals for England (column 1) have been rounded to nearest 5.

The 95% uncertainty interval corresponds to the lower (2.5th percentile) and upper (97.5th percentile) limits of the uncertainty analysis. These are shown to indicate range around the central estimate of percent of DPPs explained (column 3).

Sub-totals (in rows) for CHD patient groups.

We have assumed no change in cardiopulmonary resuscitation (CPR) uptake in the community between 2000 and 2007. Their contribution to DPPs have therefore been set to zero.

No change in uptake between 2000 and 2007.

Abbreviations: B-blocker, beta-blocker; CABG, coronary artery bypass graft; CAD, coronary artery disease; IMD, index of multiple deprivation; MI, myocardial infarction; NSTEACS, non-ST elevation acute coronary syndrome; PCI, percutaneous coronary intervention; PG, platelet glycoprotein; PTCA, percutaneous transluminal coronary angioplasty; STEMI, ST elevation myocardial infarction.